摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

甲基八氢环戊烯并[b]吡咯-2-羧酸酯 | 116404-27-4

中文名称
甲基八氢环戊烯并[b]吡咯-2-羧酸酯
中文别名
——
英文名称
octahydro-cyclopenta[b]pyrrole-2-carboxylic acid methyl ester
英文别名
methyl cis-2-aza-bicyclo[3.3.0]octane-3-carboxylate;Methyl octahydrocyclopenta[b]pyrrole-2-carboxylate;methyl 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole-2-carboxylate
甲基八氢环戊烯并[b]吡咯-2-羧酸酯化学式
CAS
116404-27-4
化学式
C9H15NO2
mdl
——
分子量
169.224
InChiKey
KHNGVUACYGTMPC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:cc456125f4fa47a345c25aae453012f7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF
    申请人:Hirata Norihiko
    公开号:US20090281331A1
    公开(公告)日:2009-11-12
    A process for producing proline derivatives of formula (1) below or acid adduct salts thereof, including: the step of reacting N-protected pyrrolidinones of formula (2) below with reducing agents to thereby obtain N-protected pyrrolidinols of formula (3) below (step A); the step of reacting the N-protected pyrrolidinols obtained in the step A with cyanating agents to thereby obtain N-protected cyanopyrrolidines of formula (4) below (step B); the step of reacting the N-protected cyanopyrrolidines obtained in the step B with alcohols and bases to thereby obtain imidates of formula (5) below and treating the imidates with acids to thereby obtain N-protected prolines of formula (6) below (step C); and the step of treating the N-protected prolines obtained in the step C with acids (step D). In formulas (1)-(6) below, any two out of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are bonded with each other to thereby form an optionally substituted C 1 -C 4 polymethylene; and R 7 is an optionally substituted C 1 -C 10 linear alkyl, etc.
    以下是生产公式(1)的脯氨酸衍生物或其酸加合物的过程,包括:将公式(2)的N-保护吡咯烷酮与还原剂反应以获得公式(3)的N-保护吡咯烷醇(步骤A);将步骤A中获得的N-保护吡咯烷醇与氰化剂反应以获得公式(4)的N-保护氰基吡咯烷(步骤B);将步骤B中获得的N-保护氰基吡咯烷与醇和碱反应以获得公式(5)的咪唑酯,并用酸处理咪唑酯以获得公式(6)的N-保护脯氨酸(步骤C);将步骤C中获得的N-保护脯氨酸用酸处理(步骤D)。在下面的公式(1)-(6)中,R1,R2,R3,R4,R5和R6中的任意两个可以彼此结合以形成可选的取代C1-C4聚亚甲基;而R7是可选的取代C1-C10线性烷基等。
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    申请人:VERTEX PHARMACEUTICALS INCORPORATED
    公开号:US20140031277A1
    公开(公告)日:2014-01-30
    The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS 3 -NS 4 A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    本发明涉及以下式I的化合物:或其药学上可接受的盐或混合物,其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此,它们通过干扰丙型肝炎病毒的生命周期发挥作用,并且还可用作抗病毒剂。本发明还涉及包含这些化合物的组合物,无论是用于体外使用还是用于治疗患有HCV感染的患者的给药,并涉及制备这些化合物的过程。本发明还涉及通过给予本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
  • PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF
    申请人:Sumitomo Chemical Company, Limited
    公开号:EP2014648A1
    公开(公告)日:2009-01-14
    A method of producing a proline derivative of the following formula (1) or an acid addition salt thereof, comprising the following four steps A to D: [wherein, any two of R1, R2, R3, R4, R5 and R6 are connected to form an optionally substituted polymethylene group having 1 to 4 carbon atoms, and R7 represents an optionally substituted linear alkyl group having 1 to 10 carbon atoms, branched alkyl group having 2 to 10 carbon atoms, linear alkenyl group having 2 to 10 carbon atoms, branched alkenyl group having 3 to 10 carbon atoms or aralkyl group having 7 to 20 carbon atoms.] (Step A) A step of reacting N-protected pyrrolidinones of the following formula (2) with a reducing agent, to produce N-protected pyrrolidinols of the following formula (3): (Step B) A step of reacting the N-protected pyrrolidinols of the formula (3) obtained in the step A with a cyanodizing agent, to produce N-protected cyanopyrrolidines of the following formula (4): (Step C) A step of reacting the N-protected cyanopyrrolidines of the formula (4) obtained in the step B with alcohols and a base, to obtain imidates of the following formula (5), and treating the imidates with an acid, to produce N-protected prolines of the following formula (6): (Step D) A step of treating the N-protected prolines of the formula (6) obtained in the step C with an acid, to produce a proline derivative of the above-described formula (1) or an acid addition salt thereof.
    一种生产下式(1)的脯氨酸衍生物或其酸加成盐的方法,包括以下四个步骤 A 至 D: [其中,R1、R2、R3、R4、R5 和 R6 中的任意两个连接形成具有 1 至 4 个碳原子的任选取代的聚亚甲基,R7 代表具有 1 至 10 个碳原子的任选取代的直链烷基、具有 2 至 10 个碳原子的支链烷基、具有 2 至 10 个碳原子的直链烯基、具有 3 至 10 个碳原子的支链烯基或具有 7 至 20 个碳原子的芳烷基。] (步骤 A) 将下式(2)的 N-保护吡咯烷酮与还原剂反应,生成下式(3)的 N-保护吡咯烷 醇: (步骤 B) 将步骤 A 中得到的式 (3) 的 N-保护吡咯烷酮与氰化剂反应,生成下式 (4) 的 N-保护氰基吡咯烷: (步骤 C) 将步骤 B 中得到的式 (4) 的 N-保护氰基吡咯烷与醇和碱反应,得到下式 (5) 的亚胺酸盐,并用酸处理亚胺酸盐,得到下式 (6) 的 N-保护脯氨酸: (步骤 D) 用酸处理步骤 C 中得到的式 (6) 的 N-保护脯氨酸,生成上述式 (1) 的脯氨酸衍生物或其酸加成盐。
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    申请人:VERTEX PHARMACEUTICALS INCORPORATED
    公开号:EP2311851A2
    公开(公告)日:2011-04-20
    The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing theses compounds.
    本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒 NS3-NS4A 蛋白酶活性的式 (I) 化合物或其药学上可接受的盐或混合物。因此,它们通过干扰丙型肝炎病毒的生命周期发挥作用,也可用作抗病毒药物。本发明还涉及包含这些化合物的组合物,这些组合物可用于体内外使用,也可用于丙型肝炎病毒感染患者,还涉及制备这些化合物的工艺。本发明还涉及通过施用包含本发明化合物的组合物治疗患者 HCV 感染的方法。本发明还涉及制备这些化合物的工艺。
  • US4849524A
    申请人:——
    公开号:US4849524A
    公开(公告)日:1989-07-18
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物